Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis

Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever

(2016) Katerina Laskari et al.   JOURNAL OF RHEUMATOLOGY

Biologic therapy in familial Mediterranean fever

(2016) Tomohiro Koga et al.   Modern Rheumatology

Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever

(2016) Orhan Kucuksahin et al.   Modern Rheumatology

Emerging treatments for amyloidosis

(2015) Rabya H. Sayed et al.   KIDNEY INTERNATIONAL

Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases

(2015) Rezan Topaloglu et al.   PEDIATRIC NEPHROLOGY

Diagnostic criteria of familial Mediterranean fever

(2014) Yackov Berkun et al.   AUTOIMMUNITY REVIEWS

Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab

(2014) Roberto Scarpioni et al.   CLINICAL RHEUMATOLOGY

Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis

(2014) Z. Birsin Özçakar et al.   CLINICAL RHEUMATOLOGY

Systemic AA amyloidosis: epidemiology, diagnosis, and management

(2014) Diego Real de Asua et al.   Clinical Epidemiology

Familial Mediterranean fever—A review

(2011) Mordechai Shohat et al.   GENETICS IN MEDICINE

Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure

(2011) K. Stankovic Stojanovic et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Recent Insights into the Pathogenesis of Type AA Amyloidosis

(2011) J. C. H. van der Hilst   TheScientificWorldJOURNAL